Testing the Addition of the Drug Nivolumab Before and After Surgery for Renal Cell Cancer

**WHO will take part in this study?**

Approximately 805 people will take part in this study. The study is open to:

- Patients with locally advanced kidney cancer (cancer is still contained within the kidney)
- Patients with limited metastatic disease (the cancer has spread beyond the kidney but only to 3 or fewer places) that can be removed or definitively treated around the same time as the surgery to remove the kidney tumor

Ask your doctor about whether this study might be an option for you.

**WHY could this study be important to you?**

This study is seeking to find out whether treatment with an immunotherapy agent, nivolumab, before and after surgery to remove a kidney tumor may reduce the likelihood of the cancer recurring and lead to better survival. Immunotherapy agents such as nivolumab stimulate the body’s immune system to help the body fight cancer. However, it is not yet known whether the addition of an immunotherapy agent to standard removal of the tumor will be more effective than surgery and observation.
**WHAT does this study involve?**

If you choose to participate in this study:

- You will receive either standard-of-care surgery to remove your kidney cancer or receive an immunotherapy drug called nivolumab before and after your standard-of-care surgery.
- You will be seen by a study doctor who will perform exams and order lab work and imaging scans at specified time points.
- Your study doctor will also navigate your care with your surgeon who is removing your kidney tumor.
- If you are registered to the arm with immunotherapy (Arm A), you will be treated with the immunotherapy agent nivolumab, with 1 dose given through the vein before the surgery and 9 doses after the surgery (approximately 9 months).
- Your study doctor will follow up with you for 10 years.

**WHAT are the costs of taking part in this study?**

- The routine costs of care required in studies such as PROSPER-RCC are usually covered by health insurance, but coverage may not be the same from plan to plan, so please discuss these issues with your healthcare provider and your insurer. If you are assigned to receive the immunotherapy (Arm A), it will be provided at no cost to you during the course of the study.
- For more information on insurance coverage and clinical trials, visit the National Cancer Institute (NCI) website at: https://www.cancer.gov/about-cancer/treatment/clinical-trials/paying or call 1-800-4-CANCER (1-800-422-6237).

**IF you would like to know more**

- About the PROSPER-RCC (EA8143) study
  - Ask your doctor.
  - Visit www.ecog-acrin.org and search EA8143, then select the link to EA8143. If you are seeking information about medical facilities where this study is available, scroll down the page to Locations and Contacts.
  - Call the NCI Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
- About clinical trials and general cancer information
  - Visit the NCI website at www.cancer.gov.

**About ECOG-ACRIN**

The ECOG-ACRIN Cancer Research Group is a scientific organization that designs and conducts biomarker-driven cancer research involving adults who have or are at risk of developing cancer. The Group is dedicated to achieving research advances in all aspects of cancer care and improving the quality of life and survival in patients. For more information about ECOG-ACRIN, visit www.ecog-acrin.org.